selected scholarly activity
-
chapters
- The T‐Body Approach: Towards Cancer Immuno‐Gene Therapy. 287-298. 2002
-
conferences
- Androgen deprivation therapy for prostate cancer, measures of adiposity and strength, and adverse cardiovascular outcomes: observations from 3000 men in 5 countries in the RADICAL PC study. European Heart Journal. 2023
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis.. JACC: CardioOncology. 70-81. 2023
- Clinical significance of alpha 2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naive men with elevated PSA level.. European Urology. S729-S731. 2022
- The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. Journal of Clinical Oncology. 2020
- Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer.. Journal of Clinical Oncology. 5015-5015. 2019
- MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER. Investigative Urology. E163-E163. 2017
- MP57-13 EARLY CARDIoVASCULAR MORBIDITY IN A PILOT PROSPECTIVE RANDOMIZED TRIAL COMPARING LHRH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER. Investigative Urology. E768-E768. 2017
- Androgen-deprivation therapy-induced atherosclerosis in prostate cancer: Differences between GnRH-agonist and antagonist. Atherosclerosis. e87-e87. 2016
- MP07-12 ABDOMINAL OBESITY, ALTERED ADIPOKYNES AND ELEVATED C-PEPTIDE LEVELS ARE ASSOCIATED WITH HIGH GLEASON SCORE IN PATIENTS UNDERGOING DIAGNOSTIC PROSTATE BIOPSY: DATA FROM PROSPECTIVE REGISTRY. Investigative Urology. E81-E81. 2016
- PD27-09 INCIDENCE AND SIGNIFICANCE OF THROMBO-EMBOLIC EVENTS IN BLADDER UROTHELIAL CARCINOMA PATIENTS UNDERGOING NEO-ADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY: RESULTS FROM MULTI-CENTRE NORTH-AMERICAN AND EUROPEAN CONTEMPORARY DATA. Investigative Urology. E652-E653. 2016
- Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. Journal of Clinical Oncology. 393-393. 2016
- The RADICAL-PC trial.. Journal of Clinical Oncology. 178-178. 2016
- Abstract 4960: ERp46 (thioredoxin domain-containing protein 5, TXND5) promotes prostate cancer growth in vitro and in vivo. Cancer Research. 4960-4960. 2015
- ERP46 MEDIATES PROSTATE CANCER TUMORIGENESIS. Journal of Urology. E439-E439. 2015
- INHIBITION OF CARBONIC ANHYDRASE IX CONFERS RADIATION SENSITIVITY TO RENAL CELL CARCINOMA. Journal of Urology. E456-E456. 2015
- Androgen Deprivation Therapy-Induced Weight Gain and Atherosclerosis in Prostate Cancer: Differences Between Orchiectomy, GnRH Agonist and Antagonist. Arteriosclerosis, Thrombosis and Vascular Biology. 2014
- The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.. Journal of Clinical Oncology. 191-191. 2014
- The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.. Journal of Clinical Oncology. 2013
- 1440 EMERGENCE OF VARIANT HISTOLOGY DURING NEO-ADJUVANT CHEMO-THERAPY FOR MUSCLE INVASIVE URETHELIAL BLADDER CANCER IS COMMON AND ASSOCIATED WITH POOR PROGNOSIS. Investigative Urology. E590-E590. 2013
- 1441 INCIDENCE, CHARACTERISTICS, AND IMPLICATIONS OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER UNDERGOING CISPLATIN BASED NEO-ADJUVANT CHEMOTHERAPY. Investigative Urology. E590-E591. 2013
- 315 ERP46 MEDIATES PROSTATE CANCER TUMORIGENESIS IN VITRO BY INHIBITING ADIPONECTIN-INDUCED TUMOR-SUPPRESSIVE EFFECTS- LINKING OBESITY TO PROSTATE CANCER. Investigative Urology. E128-E128. 2013
- 497 THE ROLE OF FSH IN CASTRATION INDUCED ADIPOGENESIS. HIGHLIGHTING DIFFERENCES BETWEEN ORCHIECTOMY, GNRH AGONISTS AND ANTAGONISTS. Investigative Urology. E204-E204. 2013
- Underexpression of Tumor Suppressor LKB1 in Clear Cell Renal Cell Carcinoma is Common and Confers Growth Advantage in vitro and in vivo. Urology. S24-S24. 2012
- 140 ERP46 MEDIATES KIDNEY CANCER TUMORIGENESIS BY INHIBITING ADIPONECTIN TUMOR SUPPRESSIVE EFFECTS. Investigative Urology. E58-E58. 2012
- 156 LKB1 DRIVES ADIPONECTIN RECEPTOR 1 (ADIPOR1) EXPRESSION IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC): FROM TUMOR DEVELOPMENT TO DISEASE CHARACTERISTICS. Investigative Urology. E64-E64. 2012
- 1448 IS THERE A ROLE FOR ROUTINE ANTERIOR ZONE SAMPLING DURING TRANSRECTAL ULTRASOUND GUIDED SATURATION PROSTATE BIOPSY?. Investigative Urology. e587-e587. 2012
- Is There a Role for Routine Anterior Zone Sampling During Transrectal Ultrasound Guided Saturation Prostate Biopsy?. Urology. S134-S135. 2012
- 1633 HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCALIZED PROSTATE CANCER: IMPACT OF NADIR PSA ON CANCER CONTROL. Investigative Urology. E655-E655. 2011
- 233 ACTIVATION OF ADIPONECTIN RECEPTOR 1 (ADIPOR1) WHICH IS UNDER-EXPRESSED IN KIDNEY CANCER INDUCES TUMOR SUPRESSION. Investigative Urology. E95-E95. 2011
- 396 PRESENCE OF GRP78 ON THE CELL SURFACE OF KIDNEY CANCER CELLS CORRELATES WITH INCREASED ANTI-GRP78 AUTOANTIBODY TITRES IN KIDNEY CANCER PATIENTS- A POTENTIAL NOVEL DIAGNOSTIC MARKER. Investigative Urology. E160-E160. 2011
- 401 ORAL APOCYNIN SENSITIZES PROSTATE CANCER XENOGRAFTS TO RADIATION. Investigative Urology. E162-E162. 2011
- 945 ORAL APOCYNIN SENSITIZES PROSTATE CANCER XENOGRAFTS TO RADIATION. European Urology Open Science. 295-296. 2011
- Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study.. Journal of Clinical Oncology. 387-387. 2011
- 1825 OBESOGENIC PROFILE OF CONTEMPORARY NORTH AMERICAN RENAL STONE PATIENTS. Investigative Urology. e732-e732. 2011
- 100 ADIPONECTIN INHIBITS OXIDATIVE STRESS IN PROSTATE CANCER CELLS. Investigative Urology. E41-E41. 2010
- 377 WHAT CAN THE HAIR FOLLICLES AND SALIVARY GLANDS TELL US ABOUT THE OXIDATIVE STRESS STATUS OF THE PROSTATE? A PRECLINICAL STEP TOWARDS INDIVIDUALIZATION OF PROSTATE CANCER PREVENTION STRATEGIES. Investigative Urology. E149-E149. 2010
- 587 ANTERIOR PROSTATE BIOPSIES REVEAL A SANCTUARY SITE OF PROSTATE CANCER IN PATIENTS WITH PREVIOUS NEGATIVE EXTENDED PROSTATE BIOPSIES. European Urology Open Science. 198-198. 2010
- 860 WHAT CAN THE HAIR FOLLICLES AND SALIVARY GLANDS TELL US ABOUT THE OXIDATIVE STRESS STATUS OF THE PROSTATE? A PRECLINICAL STEP TOWARDS INDIVIDUALIZATION OF PROSTATE CANCER PREVENTION STRATEGIES. European Urology Open Science. 273-273. 2010
- Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients. Journal of Clinical Oncology. 2009
- 2 YEARS BIOCHEMICAL FAILURE FREE SURVIVAL FOLLOWING HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) FOR LOCALIZED PROSTATE CANCER: PROSPECTIVE COHORT SINGLE CENTER STUDY OF 196 PATIENTS. Investigative Urology. 714-714. 2009
- Construction of tissue micro array from prostate needle biopsies using vertical clustering re-arrangement technique. Histopathology. 274-275. 2008
- Construction of tissue micro array from prostate needle biopsies using vertical clustering re-arrangement technique. Journal of Clinical Oncology. 22205-22205. 2008
- Correlation of computerized tomography measurement of visceral adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear cell renal cell carcinoma. Journal of Clinical Oncology. 5118-5118. 2008
- Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear cell carcinoma of the kidney. Journal of Clinical Oncology. 22225-22225. 2008
- Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib—Single center experience. Journal of Clinical Oncology. 16141-16141. 2008
- INTER-RELATED EFFECTS OF ANDROGENS, FATTY ACIDS AND OXIDATIVE STRESS IN PROSTATE CANCER - A MECHANISTIC SUPPORT FOR PREVENTION STRATEGIES. Investigative Urology. 42-42. 2008
- Expression of various drug resistance proteins in Wilms' tumor: Immunohistochemical study using TMA methodology. Virchows Archiv. 340-341. 2007
- 1289: Lower Plasma Adiponectin Levels as a Potential Biomarker for Renal Cell Carcinoma. Investigative Urology. 424-425. 2007
- Expression of Cyclooxygenase-2 in Wilms Tumor: Immunohistochemical Study Using Tissue Microarray Methodology. Investigative Urology. 1747-1750. 2006
- INHIBITION OF WILMS TUMOR XENOGRAFT PROGRESSION BY HALOFUGINONE IS ACCOMPANIED BY ACTIVATION OF WT-1 GENE EXPRESSION. Investigative Urology. 1527-1531. 2005
- Therapy of human prostate and breast carcinoma in experimental models by redirected effector lymphocytes expressing Erb-B2 specific chimeric receptors. Molecular Therapy. S119-S119. 2003
- Therapy of prostate and breast cancer using erb-B2 specific chimeric receptor expressing effector lymphocytes. The FASEB Journal. C128-C129. 2003
- Immuno-gene therapy of prostate cancer using human lymphocytes retargeted with ERBB2 specific chimeric receptors. Journal of Urology. 145-145. 2002
- Cancer immunotherapy by genetically engineered effector lymphocytes redirected by chimeric receptors. The FASEB Journal. A1200-A1200. 2001
- Redirecting genetically engineered effector lymphocytes to cancer using chimeric receptors. Cancer Gene Therapy. 1384-1384. 2000
-
journal articles
- Cardiovascular Risk in Prostate Cancer.. Cardiology Clinics. 43:83-91. 2025
- Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 6:835-846. 2024
- Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.. Prostate Cancer and Prostatic Diseases. 1-7. 2024
- Educational attainment and cardiovascular outcomes in prostate cancer: observations from 3700 men in 6 countries in the RADICAL PC study. European Heart Journal. 45:ehae666.3159. 2024
- Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio.. BMC Urology. 24:226. 2024
- Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.. JACC: CardioOncology. 6:761-771. 2024
- Cardiovascular risk in ADT recipients: does the type of ADT matter?. Prostate Cancer and Prostatic Diseases. 27:435-437. 2024
- Timing of Major Postoperative Bleeding Among Patients Undergoing Surgery. JAMA network open. 7:e244581-e244581. 2024
- Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels. JACC: Basic to Translational Science. 9:364-379. 2024
- 1821P High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients. Annals of Oncology. 34:S986-S986. 2023
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer. JACC: CardioOncology. 5:70-81. 2023
- Editorial Comment. Investigative Urology. 208:1224-1225. 2022
- Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model. Prostate Cancer and Prostatic Diseases. 25:596-596. 2022
- The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:253-262. 2022
- Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy. Investigative Urology. 207:1020-1028. 2022
- MP45-06 CLINICAL SIGNIFICANCE OF α2,3-SIALYLATED PROSTATE-SPECIFIC ANTIGEN DENSITY AND MRI FOR HIGH-GRADE PROSTATE CANCER IN BIOPSY-NAÏVE MEN WITH ELEVATED PSA LEVEL. Investigative Urology. 207:e764. 2022
- Editorial Comment. Investigative Urology. 207:850-850. 2022
- Editorial Comment. Investigative Urology. 207:849-850. 2022
- THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS. Journal of the American College of Cardiology. 79:1892-1892. 2022
- The Cardiologist's Role in the Management of Patients with a Genitourinary Cancer.. Israel Medical Association Journal. 24:175-178. 2022
- Clinical significance of α2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naïve men with elevated PSA level.. European Urology. 81:S729-S731. 2022
- Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. Prostate. 81:1411-1427. 2021
- Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition. 5:nzab106-nzab106. 2021
- Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial. The BMJ. 374:n2209-n2209. 2021
- Editorial Comment. Investigative Urology. 206:621-622. 2021
- Primary large cell neuroendocrine carcinoma of the distal ureter: A rare entity. Human Pathology: Case Reports. 25:200545-200545. 2021
- The ‘C’ Words: parallels and analogies between Prostate Cancer and Covid-19. World Journal of Urology. 39:3175-3176. 2021
- Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. Bladder Cancer. 7:261-278. 2021
- Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model. Prostate Cancer and Prostatic Diseases. 24:389-397. 2021
- Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Journal of the Canadian Urological Association. 15:181-186. 2021
- Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer and Prostatic Diseases. 24:177-185. 2021
- Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. British Journal of Anaesthesia. 126:163-171. 2021
- Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. British Journal of Anaesthesia. 126:172-180. 2021
- Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection. European Urology Open Science. 19:e514-e515. 2020
- Clinical significance of the Siaα2,3gal-glycosylated prostate-specific antigen assay for prostate cancer detection. European Urology Open Science. 19:e510-e511. 2020
- The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. European Urology Open Science. 19:e2106-e2106. 2020
- Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. Investigative Urology. 203:1109-1116. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- PD52-10 CLINICAL SIGNIFICANCE OF THE LACDINAC-GLYCOSYLATED PROSTATE-SPECIFIC ANTIGEN ASSAY FOR PROSTATE CANCER DETECTION. Investigative Urology. 203. 2020
- PD53-07 CLINICAL SIGNIFICANCE OF THE SIAα2,3GAL-GLYCOSYLATED PROSTATE-SPECIFIC ANTIGEN ASSAY FOR PROSTATE CANCER DETECTION. Investigative Urology. 203:e1099-e1099. 2020
- The opioid crisis and nudge theory. Journal of the Canadian Urological Association. 14:139-140. 2020
- The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. Journal of Clinical Oncology. 38:364-364. 2020
- Antagonizing GnRH receptors: A temporary ADT salvage maneuver for prostate cancer patients experiencing PSA failure with GnRH agonist. Journal of the Canadian Urological Association. 14:42. 2020
- Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. Investigative Urology. 202:1199-1208. 2019
- Reply By Authors. Investigative Urology. 202:1208-1208. 2019
-
Clinical significance of the Lacdi
NA c‐glycosylated prostate‐specific antigen assay for prostate cancer detection. Cancer Science. 110:2573-2589. 2019 - Clinical significant prostate cancer diagnostic performance of LacdiNAc-prostate-specific antigen glycoisomer assay at initial prostate biopsy: Retrospective multi-institutional study. European Urology Open Science. 18:e141-e142. 2019
- Cancer prevention and screening in a BRCA2-positive male to female transgender patient. Breast Journal. 24:1112-1113. 2018
- The contemporary role of lymph node dissection in the management of renal cell carcinoma. Therapeutic Advances in Urology. 10:335-342. 2018
- Editorial Comment. Investigative Urology. 200:580-580. 2018
- Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer EDITORIAL COMMENT. Journal of Urology. 200:580-580. 2018
- Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obesity Reviews. 19:1008-1016. 2018
- Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention. Bladder Cancer. 4:139-147. 2018
- MP52-17 CARDIOVASCULAR EVENTS AND BIOMARKERS IN A RANDOMIZED TRIAL COMPARING LHRH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER. Investigative Urology. 199:e702. 2018
- PD56-07 COMPARISON WITH DIAGNOSTIC PERFORMANCE BETWEEN ABERRANT GLYCOSYLATED S2,3PSA TEST AND CONVENTIONAL PSA TESTS. Investigative Urology. 199:e1064. 2018
- Comparison with diagnostic performance between aberrant glycosylated S2,3PSA test and conventional PSA tests. European Urology Open Science. 17:e552-e554. 2018
- Autoantibodies against the cell surface–associated chaperone GRP78 stimulate tumor growth via tissue factor. Journal of Biological Chemistry. 292:21180-21192. 2017
- Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]. European Journal of Cancer. 83:335-335. 2017
- Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. CMAJ open. 5:E594-E603. 2017
- Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. Oncology Letters. 13:3624-3630. 2017
- The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations. 35:183-191. 2017
- An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. International Journal of Molecular Sciences. 18:470-470. 2017
- Elevated C‐Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer. Prostate. 77:211-221. 2017
- Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?. Journal of the Canadian Urological Association. 11:39-39. 2017
- Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. European Journal of Cancer. 70:62-74. 2017
- Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. Investigative Urology. 196:1627-1633. 2016
- A prospective evaluation of obesometric parameters associated with renal stone recurrence. Journal of the Canadian Urological Association. 10:234-234. 2016
- Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?. Therapeutic Advances in Urology. 8:118-129. 2016
- Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. Cancer Research. 76:1603-1614. 2016
- Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer. European Urology. 69:177-178. 2016
- Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.. European Urology. 69:177-178. 2016
- Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urologic Oncology: Seminars and Original Investigations. 33:464-475. 2015
- Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncology Reports. 34:1968-1976. 2015
- Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?. Investigative Urology. 193:1882-1883. 2015
- MP37-05 ERP46 MEDIATES PROSTATE CANCER TUMORIGENESIS. Investigative Urology. 193:e439. 2015
- MP39-05 INHIBITION OF CARBONIC ANHYDRASE IX CONFERS RADIATION SENSITIVITY TO RENAL CELL CARCINOMA. Investigative Urology. 193:e456. 2015
- Follicle stimulating hormone (FSH): A potential surrogate marker for androgen deprivation therapy (ADT) oncological and systemic effects.. Journal of the Canadian Urological Association. 9:226-226. 2015
- Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects. Journal of the Canadian Urological Association. 9:E226-E227. 2015
- The relative contribution of urine extravasation to elevation of plasma creatinine levels in acute unilateral ureteral obstruction. Journal of the Canadian Urological Association. 9:428-428. 2015
- GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model1Contributed equally and share first authorship.. Urologic Oncology: Seminars and Original Investigations. 32:1126-1134. 2014
- Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations. 32:975-980. 2014
- Abstract 596: Androgen Deprivation Therapy--Induced Weight Gain and Atherosclerosis in Prostate Cancer: Differences Between Orchiectomy, GnRH Agonist and Antagonist. Arteriosclerosis, Thrombosis and Vascular Biology. 34. 2014
- 308 The role of FSH in castration-induced weight gain and cardiovascular disease: Differences between orchiectomy, GnRH agonists and antagonists. European Urology Open Science. 13:e308-e308. 2014
- MP20-09 SUGGESTIVE MECHANISM OF RISING PLASMA CREATININE FOLLOWING AN ACUTE UNILATERAL URETERAL OBSTRUCTION – A RAT MODEL. Investigative Urology. 191:e199. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Underactivation of the adiponectin–adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression. Clinical and Experimental Metastasis. 31:169-183. 2014
- Endoplasmic Reticulum Protein ERp46 in Renal Cell Carcinoma. PLoS ONE. 9:e90389-e90389. 2014
- Is there a role for anterior zone sampling as part of saturation trans-rectal ultrasound guided prostate biopsy?. BMC Urology. 14:34-34. 2014
- Erratum: Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer and Prostatic Diseases. 16:398-398. 2013
- Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer and Prostatic Diseases. 16:217-225. 2013
- The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.. Journal of Clinical Oncology. 31:e16011-e16011. 2013
- 939 ERp46 mediates prostate cancer tumorigenesis in vitro by inhibiting adiponectin-induced tumor-suppressive effects – linking obesity to prostate cancer. European Urology Open Science. 12:e939-e939. 2013
- Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. British Journal of Cancer. 108:327-333. 2013
- Buried penis: An unrecognized risk factor in the development of invasive penile cancer.. Journal of the Canadian Urological Association. 6:E199-E202. 2012
- Single‐session primary high‐intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation‐based technology. BJU International. 110:1142-1148. 2012
- Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’. Journal of the American Medical Association (JAMA). 307:2590-2590. 2012
- Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer and Prostatic Diseases. 15:28-35. 2012
- Anterior-entry Abdominoperineal Resection: A Variation in the Method of Perineal Dissection. Annals of Surgical Oncology. 19:794-800. 2012
- Obesometric factors associated with increased skin-to-stone distances in renal stone patients. Canadian Journal of Urology. 19:6554-6559. 2012
- The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. British Journal of Radiology. 85:1-10. 2012
- Construction of tissue micro array from prostate needle biopsies using the vertical clustering re‐arrangement technique. Prostate. 71:1374-1381. 2011
- Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Journal of the Canadian Urological Association. 5:274-282. 2011
- ADT and the metabolic syndrome: no good deed goes unpunished. Journal of the Canadian Urological Association. 5:33-33. 2011
- What Can Surrogate Tissues Tell Us about the Oxidative Stress Status of the Prostate? A Hypothesis-Generating In-Vivo Study. PLoS ONE. 5:e15880-e15880. 2010
- Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: A mechanistic model supporting prevention strategies. International Journal of Oncology. 37:761-766. 2010
- Abstract 5099: Adiponectin inhibits oxidative stress in prostate cancer cells. Cancer Research. 70:5099-5099. 2010
- Abstract 70: Mitochondrial localization of adiponectin receptor 1 (AdipoR1) induces apoptosis in cancer cells. Cancer Research. 70:70-70. 2010
- Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer and Prostatic Diseases. 13:39-46. 2010
- Bulbocavernosus reflex testing: a preliminary study on the prognostic factors for potency and response to sildenafil citrate after bilateral nerve-sparing radical prostatectomy. International Urology and Nephrology. 42:39-45. 2010
- The case for prostate capsule-sparing radical cystectomy in selected patients. Journal of the Canadian Urological Association. 3:215-215. 2009
- The case for prostate capsule-sparing radical cystectomy in selected patients. Journal of the Canadian Urological Association. 3. 2009
- Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. Expert Review of Anticancer Therapy. 9:975-987. 2009
- Testosterone and Prostate Cancer: Revisiting Old Paradigms. European Urology. 56:48-56. 2009
- Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients. Journal of Clinical Oncology. 27:5117-5117. 2009
- Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. Current Oncology. 16:S60-S66. 2009
- ADIPONECTIN INHIBITS INVASION AND MIGRATION OF HUMAN RENAL CELL CARCINOMA THROUGH INHIBITION OF MATRIX METALLOPROTEASES (MMP) 2&9 EXPRESSION AND ACTIVITIES AND INDUCTION OF THEIR INHIBITORS (TIMP) 1&2. Investigative Urology. 181:36-36. 2009
- ADIPONECTIN INHIBITS VEGF SECRETION FROM HUMAN RENAL CELL CARCINOMA. Investigative Urology. 181:38-38. 2009
- ANDROGENS INDUCE OXIDATIVE STRESS IN PROSTATE CANCER CELLS THOUGH NADPH OXIDASE. Investigative Urology. 181:92-93. 2009
- Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma. Current Urology. 2:188-193. 2009
- Editorial Comment on: Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin Receptor. European Urology. 55:450-451. 2009
- Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Current Oncology. 16:S62-S68. 2009
- Discovery of Novel Hypermethylated Genes in Prostate Cancer Using Genomic CpG Island Microarrays. PLoS ONE. 4:e4830-e4830. 2009
- POD-6.11: Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Presence of Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma. Urology. 72:S54-S54. 2008
- POD-6.12: Progression Free Survival in Patients with Metastatic and Recurrent Renal Cancer Treated with Sorafenib: Single Center Experience. Urology. 72:S54-S54. 2008
- Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney. European Urology. 54:866-874. 2008
- EXPRESSION OF MULTIDRUG RESISTANCE-RELATED PROTEIN (MRP-1), LUNG RESISTANCE-RELATED PROTEIN (LRP) AND TOPOISOMERASE-II (TOPO-II) IN WILMS' TUMOR: IMMUNOHISTOCHEMICAL STUDY USING TMA METHODOLOGY. Biomedical Papers. 152:47-51. 2008
- Editorial Comment on: Photodynamic Diagnosis in Urology: State-of-the-Art. European Urology. 53:1149-1150. 2008
- To Bury the Knot, Then, Is Better Than Not. Urology. 71:1206-1208. 2008
- Androgen‐dependent regulation of medium and long chain fatty acids uptake in prostate cancer. Prostate. 67:1330-1338. 2007
- The question of repeat biopsies. Journal of the Canadian Urological Association. 1:250. 2007
- Expression of various cellular markers in genitourinary rhabdomyosarcoma: immunohistochemical study using tma methodology. Journal of Pediatric Urology. 3:S41-S42. 2007
- Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Molecular Cancer Therapeutics. 6:570-577. 2007
- Androgen Induces Adaptation to Oxidative Stress in Prostate Cancer: Implications for Treatment with Radiation Therapy. Neoplasia. 9:68-80. 2007
- Diagnosis of Prostate Cancer. Recent Results in Cancer Research. 175:83-99. 2007
- Prostate Cancers Scored as Gleason 6 on Prostate Biopsy are Frequently Gleason 7 Tumors at Radical Prostatectomy: Implication on Outcome. Investigative Urology. 176:979-984. 2006
- Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Research. 66:6040-6049. 2006
- Cardiovascular effects of androgen depletion and replacement therapy. Urology. 67:1126-1132. 2006
- Population Based Survival Data on Urachal Tumors. Investigative Urology. 175:2042-2047. 2006
- 795: Androgens Induce Adaptation to Oxidative Stress-Implications for Prostate Cancer Radiation Therapy. Investigative Urology. 175:257-257. 2006
- PROSTATE CANCERS SCORED AS GLEASON 6 IN PROSTATE BIOPSY ARE FREQUENTLY GLEASON 7 TUMOURS AT RADICAL PROSTATECTOMY: IMPLICATION ON OUTCOME. European Urology Open Science. 5:315-315. 2006
- Photodynamic Therapy for Urological Malignancies: Past to Current Approaches. Investigative Urology. 175:1201-1207. 2006
- THE SIGNIFICANCE OF NEGATIVE AMACR STAINING IN PROSTATE CANCER: SORTING NEUROENDOCRINE PROSTATIC CANCER IN CHALLENGING DIAGNOSTIC CASES. European Urology Open Science. 5:241-241. 2006
- Prostate sparing radical cystectomy--not for all, but an option for some.. Canadian Journal of Urology. 13 Suppl 1:81-87. 2006
- Testicular Fixation Following Torsion of the Spermatic Cord???Does it Guarantee Prevention of Recurrent Torsion Events?. Investigative Urology. 175:171???174-171???174. 2006
- Testicular Fixation Following Torsion of the Spermatic Cord—Does it Guarantee Prevention of Recurrent Torsion Events?. Investigative Urology. 175:171-173. 2006
- Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells.. DISCOVERY MEDICINE. 5:259-264. 2005
- 723: Retroperitoneal Sympathetic Nerve Grafting (RSNG) for None-Nerve Sparing Retroperitoneal Lymphadenectomy for Testis Cancer: Preliminary Report. Investigative Urology. 173:197-197. 2005
- Effects of intravesical chemotherapy and immunotherapy on semen analysis. Urology. 65:765-767. 2005
- The role of indirect radionuclide cystography during the acute phase of pyelonephritis in young women. BJU International. 95:619-623. 2005
- Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114:1774-1781. 2004
- Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114:1774-1781. 2004
- ErbB2 IS A TUMOR ASSOCIATED ANTIGEN AND A SUITABLE THERAPEUTIC TARGET IN WILMS TUMOR. Investigative Urology. 172:1644-1648. 2004
- ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. Journal of Urology. 172:1644-1648. 2004
- [Lower urinary tract reconstruction by augmentation cystoplasty and insertion of artificial urinary sphincter cuff only: long term follow-up].. The French Journal of Urology. 14:310-314. 2004
- Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker. Neoplasia. 6:224-233. 2004
- Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker. Neoplasia. 6:224-233. 2004
- 596: Is there a Role for Androgen Ablative Therapy for Hormone Refractory Prostate Cancer?. Investigative Urology. 171:158-158. 2004
- Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.. Cancer Research. 63:2470-2476. 2003
- Photodynamic therapy with Pd‐bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts. International Journal of Cancer. 104:782-789. 2003
- Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.. Cancer Research. 62:6803-6807. 2002
- Lack of MHC expression and retention of ultrastructural characteristics by xenograft transmissible venereal tumor cells in SCID mice. Veterinary Immunology and Immunopathology. 86:245-249. 2002
- Growth inhibition of prostate cancer xenografts by halofuginone*†. Prostate. 51:73-83. 2002
- Use of a murine xenograft model for canine transmissible venereal tumor. American Journal of Veterinary Research. 62:907-911. 2001
- WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.. Cancer Research. 60:6563-6567. 2000
- [Malignant lymphoma of the bladder].. Harefuah. 136:543-587. 1999
- [The use of various diagnostic modalities for evaluation of acute torsion of the testis].. Harefuah. 136:158-160. 1999
- [The Mitrofanoff pouch in lower urinary tract reconstruction].. Harefuah. 135:492-568. 1998
- [Transrectal ultrasound-controlled needle aspiration of a prostatic cyst].. Harefuah. 130:310-359. 1996
- ADT and the metabolic syndrome: no good deed goes unpunished. Journal of the Canadian Urological Association. 5:33-33.
- Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Journal of the Canadian Urological Association. 5:274-274.
-
preprints